1. Scrip
  2. >>Business

‘We’ll Be First With Off-The-Shelf CAR-T,’ Vows Precision Biosciences – And Hopes To Win Over Gene-Editing Skeptics

Aiming To Help Patients Who Fail Auto CAR-Ts

 
• By Andrew McConaghie

As it and its competitors have failed on the first test of durability with their allogeneic CAR-T candidates, Precision Biosciences is looking to cross the line in a sub-group of responders – as well as prove the value of its gene-editing platform.

Precision Biosciences
Precision Biosciences has seen its share price fall sharply in 2022, but hopes it can be the first to bring an allogeneic CAR-T to market, and prove the value of its gene-editing platform. • Source: Alamy

Among the three frontrunner companies in the race to have the first-in-class ‘off-the-shelf’ CAR-T therapy approved, Precision BioSciences is currently the least fancied by investors – but its leadership is convinced they will be first to achieve the elusive goal.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

BMS Makes Dealmaking A Top Priority As Doubts About Growth Increase

 
• By Mandy Jackson

Bristol’s CEO Christopher Boerner says business development is the company’s biggest spending priority as analysts raise concerns about growth, citing a need for BMS to do more deals.

AbbVie Increases US Manufacturing, But Says It’s Not Because Of Tariffs

 
• By Joseph Haas

CEO Robert Michael said AbbVie is positioned strongly to handle current and potentially upcoming tariffs, while committing $10bn to increased US manufacturing sites.

Merck KGaA Moves Closer To Sealing SpringWorks Buy

 
• By Kevin Grogan

The German group could pay $3.5bn to get hold of the US firm and its two approved products.

In Brief: Mosaic Gains Two Clinical-Stage Oncology Assets From Astex

 
• By Sushmita Panda

Mosaic Therapeutics has in-licensed two clinical-stage oncology assets from Astex Pharmaceuticals to develop proprietary combination therapies for hard-to-treat cancers. The deal includes up to a 22% equity stake for Astex, future revenue sharing, and a planned clinical study in 2026.

More from Scrip

Merck KGaA Moves Closer To Sealing SpringWorks Buy

 
• By Kevin Grogan

The German group could pay $3.5bn to get hold of the US firm and its two approved products.

In Brief: Mosaic Gains Two Clinical-Stage Oncology Assets From Astex

 
• By Sushmita Panda

Mosaic Therapeutics has in-licensed two clinical-stage oncology assets from Astex Pharmaceuticals to develop proprietary combination therapies for hard-to-treat cancers. The deal includes up to a 22% equity stake for Astex, future revenue sharing, and a planned clinical study in 2026.

Executives On The Move: Ten CMOs And Three CEOs and CFOs Each Among This Week’s Changes

Recent moves in the industry include C-suite changes at Dyne Therapeutics, City Therapeutics and ProQR Therapeutics, plus Madrigal Pharmaceuticals acquires chief medical officer from Novartis.